<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221390</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2003-3096</org_study_id>
    <nct_id>NCT00221390</nct_id>
  </id_info>
  <brief_title>Trial of Ropinirole in Motor Recovery After Stroke</brief_title>
  <official_title>Randomized, Placebo-controlled, Double-blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy, as well as safety, of Ropinirole in
      improving movement among patients with chronic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is a leading cause of disability. Current treatments target injury and must be
      delivered within hours. A body of literature suggests that there are processes ongoing
      days-months after stroke that can be targeted therapeutically, and improve function. The
      current study evaluates one such potential therapy, the dopamine agonist ropinirole. The
      current study tests the hypothesis that patients with chronic stroke randomized to
      ropinirole+physiotherapy will show improved gait velocity over the 12 weeks of study
      participation as compared to patients randomized to placebo+physiotherapy. A secondary aim is
      to test the hypothesis that ropinirole will improve three secondary endpoints at 12 weeks
      after study entry: the proportion of patients with no significant disability (Barthel Index ≥
      95); overall motor status, measured with the arm/leg FM score; and overall physical function,
      defined as the score on the Stroke Impact Scale-16 (SIS-16). This study will also evaluate
      the safety of ropinirole in patients recovering from stroke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>Measured at weeks 1, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg motor Fugl-Meyer scale</measure>
    <time_frame>Measured at baseline and weeks 1, 2, 4, 6, 7, 8, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale-16</measure>
    <time_frame>Measured at weeks 1, 4, 7, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait endurance</measure>
    <time_frame>Measured at weeks 1, 2, 4, 6, 7, 8, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale</measure>
    <time_frame>Measured at baseline and weeks 1, 2, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <condition>Hemiparesis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole (+ physical therapy)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(vs.) Placebo + physical therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stroke onset 4 weeks-12 months prior

          2. Stroke is radiologically confirmed as either (a) ischemic or (b) hemorrhagic

          3. Minimum age 18

          4. No significant pre-stroke disability

          5. No other stroke in previous 3 months

          6. Absence of major depression

          7. Fugl-Meyer (FM) motor score of 23-83 out of 100

          8. Functional Independence Measure (FIM) ambulation-subscore of 3 or more, and 50 foot
             walk takes longer than 15 seconds

        Exclusion Criteria:

          1. Significant daytime somnolence or any substantial decrease in alertness, language
             reception, or attention

          2. Pregnant or lactating

          3. Advanced liver, kidney, cardiac, or pulmonary disease

          4. Orthostatic hypotension

          5. Current use of ciprofloxacin, a centrally acting dopamine agonist, or a centrally
             active dopamine antagonist

          6. A terminal medical diagnosis consistent with survival &lt; 1 year

          7. Coexistent major neurological disease

          8. Coexistent major psychiatric disease

          9. A history of significant alcohol or drug abuse in the prior 3 years

         10. A coexistent disease characterized by an abnormality of CNS dopaminergic tone

         11. Current enrollment in another investigational study related to stroke or stroke
             recovery

         12. Contraindication to ropinirole prescription
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven C Cramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gresham GE, Duncan PW, Stason WB, Adams HP, Adelman AM, Alexander DN, Bishop DS, Diller L, Donaldson NE, Granger CV, Holland AL, Kelly-Hayes M, McDowell FH, Myers L, Phipps MA, Roth EJ, Siebens HC, Tarvin GA, Trombly CA. Post-Stroke Rehabilitation. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, 1995.</citation>
  </reference>
  <reference>
    <citation>Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke. 2002 Nov;33(11):2718-21.</citation>
    <PMID>12411667</PMID>
  </reference>
  <reference>
    <citation>Dobkin BH. Neurologic Rehabilitation. Philadelphia: FA Davis, 1996</citation>
  </reference>
  <reference>
    <citation>Nudo RJ. Recovery after damage to motor cortical areas. Curr Opin Neurobiol. 1999 Dec;9(6):740-7. Review.</citation>
    <PMID>10607636</PMID>
  </reference>
  <reference>
    <citation>Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci. 2000 Jun;23(6):265-71. Review.</citation>
    <PMID>10838596</PMID>
  </reference>
  <reference>
    <citation>Finklestein S, Campbell A, Baldessarini RJ, Moya KL, Haber SN. Late changes in cerebral monoamine metabolism following focal ventrolateral cerebrocortical lesions in rats. Brain Res. 1985 Oct 7;344(2):205-10.</citation>
    <PMID>2412650</PMID>
  </reference>
  <reference>
    <citation>Finklestein S, Campbell A, Stoll AL, Baldessarini RJ, Stinus L, Paskevitch PA, Domesick VB. Changes in cortical and subcortical levels of monoamines and their metabolites following unilateral ventrolateral cortical lesions in the rat. Brain Res. 1983 Jul 25;271(2):279-88.</citation>
    <PMID>6193832</PMID>
  </reference>
  <reference>
    <citation>Boyeson MG, Feeney DM. Striatal dopamine after cortical injury. Exp Neurol. 1985 Aug;89(2):479-83.</citation>
    <PMID>4018214</PMID>
  </reference>
  <reference>
    <citation>Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke. 1998 Nov;29(11):2381-93; discussion 2393-5.</citation>
    <PMID>9804653</PMID>
  </reference>
  <reference>
    <citation>Cramer SC, Nelles G, Benson RR, Kaplan JD, Parker RA, Kwong KK, Kennedy DN, Finklestein SP, Rosen BR. A functional MRI study of subjects recovered from hemiparetic stroke. Stroke. 1997 Dec;28(12):2518-27.</citation>
    <PMID>9412643</PMID>
  </reference>
  <reference>
    <citation>Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982 Aug 27;217(4562):855-7.</citation>
    <PMID>7100929</PMID>
  </reference>
  <reference>
    <citation>Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci. 2000 May;27(2):97-105. Review.</citation>
    <PMID>10830340</PMID>
  </reference>
  <reference>
    <citation>Goldstein LB. Potential impact of drugs on poststroke motor recovery. In: L. B. Goldstein, ed. Restorative Neurology. Advances in pharmacotherapy for recovery after stroke. Armonk, NY: Futura Publishing Co., 1998:241-256.</citation>
  </reference>
  <reference>
    <citation>Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001 Sep 8;358(9284):787-90.</citation>
    <PMID>11564483</PMID>
  </reference>
  <reference>
    <citation>Sullivan KJ, Knowlton BJ, Dobkin BH. Step training with body weight support: effect of treadmill speed and practice paradigms on poststroke locomotor recovery. Arch Phys Med Rehabil. 2002 May;83(5):683-91.</citation>
    <PMID>11994808</PMID>
  </reference>
  <reference>
    <citation>Richards C, Malouin F, Dumas F, Tardif D. Gait velocity as an outcome measure of locomotor recovery after stroke. In: C. R and O. C, eds. Gait Analysis: Theory and Application. St. Louis: Mosby, 1995:355-364.</citation>
  </reference>
  <reference>
    <citation>Potter JM, Evans AL, Duncan G. Gait speed and activities of daily living function in geriatric patients. Arch Phys Med Rehabil. 1995 Nov;76(11):997-9.</citation>
    <PMID>7487453</PMID>
  </reference>
  <reference>
    <citation>Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002 May;67(1):53-83. Review.</citation>
    <PMID>12126656</PMID>
  </reference>
  <reference>
    <citation>Medico M, De Vivo S, Tomasello C, Grech M, Nicosia A, Castorina M, D'Agata MA, Rampello L, Lempereur L, Drago F. Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury. Eur Neuropsychopharmacol. 2002 Jun;12(3):187-94.</citation>
    <PMID>12007669</PMID>
  </reference>
  <reference>
    <citation>Bracha HS, Lyden PD, Khansarinia S. Delayed emergence of striatal dopaminergic hyperactivity after anterolateral ischemic cortical lesions in humans; evidence from turning behavior. Biol Psychiatry. 1989 Feb 1;25(3):265-74.</citation>
    <PMID>2914151</PMID>
  </reference>
  <reference>
    <citation>Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35-49. Review.</citation>
    <PMID>6367973</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Steven C. Cramer, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>Chronic stroke with hemiparesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

